MKP peptide

Cardiovascular In trials Human trials

Also called Met-Lys-Pro

A three-amino-acid peptide released when the milk protein casein is digested. It inhibits ACE, an enzyme that raises blood pressure, and can be absorbed when taken by mouth. Because brain ACE activity is linked to cognitive decline, it has also been tested for memory and orientation.

Evidence at a glance

Evidence
Human trials — Studied in people
Status
Reached clinical trials
Dosing
No human study has set a dose

Human work used it as a food ingredient at small doses.

What studies report

How it works

Inhibits ACE, including in the brain, where raised ACE activity is associated with neurodegeneration. Being only three amino acids, it survives digestion and is absorbed intact.

Binds a receptor on the cell surface and signals inward

Where it acts

Acts in blood vessels, throughout the body

The library groups this compound under Cardiovascular. The diagram shows that target, not every tissue it reaches.

Illustrated

AI-generated subject illustration; not a depiction of the compound or evidence of its effects.

Why people take it

Blood pressureCognitive protection

Reasons people seek it out — not a list of proven effects.

Status: Animal studies and small human trials as a food-derived ingredient.

Route
Oral — it survives digestion, unusually for a peptide
Sequence
Met-Lys-Pro
Formula
C16H30N4O4S
Molecular weight
374.5 g/mol
Available as
10 mg

Search PubMed for MKP peptide → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.